These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 26363980)
1. New Zealand patients' understanding of brand substitution and opinions on copayment options for choice of medicine brand. Lessing C; Ashton T; Davis P Aust Health Rev; 2016 Jun; 40(3):345-350. PubMed ID: 26363980 [TBL] [Abstract][Full Text] [Related]
2. The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand. Lessing C; Ashton T; Davis PB J Prim Health Care; 2015 Jun; 7(2):94-101. PubMed ID: 26125054 [TBL] [Abstract][Full Text] [Related]
3. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO Value Health; 2012; 15(5):664-73. PubMed ID: 22867775 [TBL] [Abstract][Full Text] [Related]
4. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting. Rathe JØ Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397 [TBL] [Abstract][Full Text] [Related]
5. Evaluating pharmacists' views, knowledge, and perception regarding generic medicines in New Zealand. Babar ZU; Grover P; Stewart J; Hogg M; Short L; Seo HG; Rew A Res Social Adm Pharm; 2011 Sep; 7(3):294-305. PubMed ID: 21272551 [TBL] [Abstract][Full Text] [Related]
6. Exploring pharmacists' opinions regarding PHARMAC's interventions in promoting brand changes. Babar ZU; Polwin A; Kan SW; Amerasinghe N; McCarthy S; Rasheed F; Stewart J; Lessing C; Ragupathy R; Scahill SL Res Social Adm Pharm; 2015; 11(1):96-110. PubMed ID: 24811426 [TBL] [Abstract][Full Text] [Related]
7. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand. Lessing C; Ashton T; Davis P Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492 [TBL] [Abstract][Full Text] [Related]
8. Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment. Lessing C; Ashton T; Davis P Adm Policy Ment Health; 2015 Nov; 42(6):695-703. PubMed ID: 25331449 [TBL] [Abstract][Full Text] [Related]
9. An Evaluation of Health Service Impacts Consequent to Switching from Brand to Generic Venlafaxine in New Zealand under Conditions of Price Neutrality. Lessing C; Ashton T; Davis P Value Health; 2015 Jul; 18(5):646-54. PubMed ID: 26297093 [TBL] [Abstract][Full Text] [Related]
10. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia. Doshi JA; Li P; Desai S; Marcus SC J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299 [TBL] [Abstract][Full Text] [Related]
11. Exploring the opinions and experiences of patients with generic substitution: a representative study of Polish society. Drozdowska A; Hermanowski T Int J Clin Pharm; 2015 Feb; 37(1):68-75. PubMed ID: 25428446 [TBL] [Abstract][Full Text] [Related]
12. How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics? Sun J; Ren L; Wirtz V J Med Econ; 2016 Sep; 19(9):881-8. PubMed ID: 27100310 [TBL] [Abstract][Full Text] [Related]
13. Evaluating patients', physicians' and pharmacy professionals' perception and concern regarding generic medicines in Gondar town, northwest Ethiopia: A multi-stakeholder, cross-sectional survey. Gebresillassie BM; Belachew SA; Tefera YG; Abebe TB; Mekuria AB; Haile KT; Erku DA PLoS One; 2018; 13(11):e0204146. PubMed ID: 30403668 [TBL] [Abstract][Full Text] [Related]
14. Unintended consequences of a Medicaid prescription copayment policy. Lieberman DA; Polinski JM; Choudhry NK; Avorn J; Fischer MA Med Care; 2014 May; 52(5):422-7. PubMed ID: 24686394 [TBL] [Abstract][Full Text] [Related]
15. Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate. Mager DE; Cox ER Am J Manag Care; 2007 Jun; 13(6 Pt 2):347-52. PubMed ID: 17567235 [TBL] [Abstract][Full Text] [Related]
16. Pharmacists' views and reported practices in relation to a new generic drug substitution policy in Lebanon: a mixed methods study. El-Jardali F; Fadlallah R; Morsi RZ; Hemadi N; Al-Gibbawi M; Haj M; Khalil S; Saklawi Y; Jamal D; Akl EA Implement Sci; 2017 Feb; 12(1):23. PubMed ID: 28212657 [TBL] [Abstract][Full Text] [Related]
17. Greek students' attitudes, perception and knowledge regarding generic medicines in times of economic crisis: a cross-sectional study. Domeyer PJ; Katsari V; Sarafis P; Aletras V; Niakas D BMC Med Educ; 2018 Nov; 18(1):262. PubMed ID: 30442145 [TBL] [Abstract][Full Text] [Related]
18. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia. McManus P; Birkett DJ; Dudley J; Stevens A Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489 [TBL] [Abstract][Full Text] [Related]
19. Consumer choice between common generic and brand medicines in a country with a small generic market. Fraeyman J; Peeters L; Van Hal G; Beutels P; De Meyer GR; De Loof H J Manag Care Spec Pharm; 2015 Apr; 21(4):288-96. PubMed ID: 25803762 [TBL] [Abstract][Full Text] [Related]
20. Evaluating community pharmacists' perspectives and practices concerning generic medicines substitution in Saudi Arabia: A cross-sectional study. Alkhuzaee FS; Almalki HM; Attar AY; Althubiani SI; Almuallim WA; Cheema E; Hadi MA Health Policy; 2016 Dec; 120(12):1412-1419. PubMed ID: 28228231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]